Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | GRM5 | P41594 | 7/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781659 | 0.89 | CYP1A2 (0.87) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL135728 | 0.87 | LMNA (0.76) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL6951312 | 0.87 | LMNA (0.76) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL29577310 | 0.86 | CYP1A2 (1.00) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL5795083 | 0.86 | CYP1A2 (1.00) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL6708175 | 0.86 | CYP1A2 (1.00) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL3434185 | 0.85 | LMNA (0.73) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| Hydrochloric Acid SCHEMBL27538332 | 0.84 | CYP1A2 (0.97) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL2898307 | 0.82 | CYP1A2 (0.75) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL6110694 | 0.82 | CYP1A2 (0.75) | LMNACYP1A2CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590985-B1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2014-05-14 | — | — | EP | disclosed |
| US-8580962-B2 | Spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | disclosed |
| EP-2590985-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2013-05-15 | — | — | EP | disclosed |
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | disclosed |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD. (IT) | 2012-03-08 | — | — | US | disclosed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
| WO-2012004400-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-01-12 | — | — | WO | disclosed |
| EP-2178858-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2011-12-28 | — | — | EP | disclosed |
| CN-101821256-A | Novel heterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD | 2010-09-01 | — | — | CN | disclosed |
| EP-2178858-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2010-04-28 | — | — | EP | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
| WO-2009015897-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | GRM5, GRIK5, GRM3 | LMNA 3472/4885CYP1A2 3224/4885CYP2C9 1779/4885 |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GPR65, GRIK5 | LMNA 2819/4885CYP1A2 3174/4885CYP2C9 2562/4885 |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | LMNA 1601/4885CYP1A2 1668/4885CYP2C9 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.